GHRP-6: Research Overview

GHRP-6 was the first specific synthetic peptide demonstrated to dose-dependently stimulate growth hormone release both in vitro and in vivo. Developed from Cyril Bowers' laboratory investigations of enkephalin-derived opioid analogues in the 1970s–80s, GHRP-6 established the pharmacological concept that GH secretion could be potently triggered through a receptor distinct from the GHRH receptor. It is notable not only as the founding compound of the GHRP class but also for its pronounced appetite-stimulation effect — one of the most consistently documented properties across multiple species. GHRP-6 is not FDA-approved for any indication and has no ongoing phase 3 clinical program; it is classified as a research chemical.

What is GHRP-6?

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a six-residue amidated peptide with a molecular weight of approximately 873.02 Da. It was originally synthesized as a partial enkephalin analogue and later found to be a potent agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor later identified as the native ghrelin receptor. GHRP-6 is structurally distinct from GHRP-2 and ipamorelin but shares the hexapeptide amide scaffold common to early synthetic GHRPs. It is sold by research-chemical vendors as lyophilized powder and carries no approved therapeutic indication.

Mechanism of Action

GHRP-6 activates GHS-R1a, a Gq/11-protein-coupled receptor expressed on pituitary somatotrophs and in the hypothalamus. Receptor occupation triggers phospholipase C → IP3 → intracellular calcium release, driving GH exocytosis. The GH response is potentiated approximately 10-fold when GHRP-6 is co-administered with exogenous GHRH, reflecting synergy between the calcium/PLC and cAMP/PKA signaling cascades. Critically, GHRP-6 binds GHS-R1a in hypothalamic regions that govern appetite and energy balance, which explains its robust orexigenic (appetite-stimulating) effect — an effect mediated through NPY/AgRP neuronal circuitry and distinct from its pituitary GH-releasing action.

What the Research Shows

The pharmacological characterization of GHRP-6 originates with Bowers et al., who published foundational structure-activity data establishing the compound's GH-releasing potency in the 1980s and 1990s (Bowers, Clin Pharmacol Ther, 1990; summarized in Bowers, Major Reference Works, Wiley). The appetite-stimulating effect has been confirmed in multiple animal models: intra-cerebroventricular injection of GHRP-6 in rodents significantly stimulates food intake, an effect also observed with the endogenous ligand ghrelin (Wren et al., 2001; PMID 11751604). Smith et al. demonstrated that GHS-R1a is the molecular target for both GHRP-6 and ghrelin (PMID 15070777), cementing the receptor pharmacology of the class.

The safety and efficacy of GH secretagogues including GHRP-6 was reviewed by Sigalos and Pastuszak (2018; PMC5632578), who noted that available studies indicate GHSs are generally well tolerated but raise concerns about insulin sensitivity with chronic use. GHRP-6 elevates cortisol and prolactin at GH-releasing doses — a less selective profile than ipamorelin (Raun et al., 1998). No phase 2 or phase 3 clinical program for GHRP-6 is present in published literature, and no regulatory filing has been made for therapeutic approval.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Published dose-finding studies are limited; values reported here come from older pharmacological literature and have not been validated in modern clinical trials. Early human studies cited in Bowers' review used intravenous doses in the low-microgram-per-kilogram range for GH provocation. The appetite-stimulation literature primarily used intracerebroventricular administration in rodents and does not translate directly to human dosing guidance. No published human dose-finding trial for subcutaneous GHRP-6 administration exists to this author's knowledge.

References

Citations for this guide are listed below. All PubMed links resolve to the NCBI abstract page for the referenced article.